CG-549 Tablet Pharmacokinetics Study: An Open-label, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of a Tablet Formulation of CG-549 in Healthy Subjects
Latest Information Update: 03 Jun 2022
At a glance
- Drugs Nilofabicin (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Pharmacokinetics
- Sponsors CrystalGenomics
Most Recent Events
- 03 Jun 2022 New trial record